Jack Duffy O'brien, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 8685 Erie Rd, Angola, NY 14006 Phone: 716-549-4454 |
Ashley Marie Norman Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 8505 Erie Rd, Angola, NY 14006 Phone: 716-549-1099 |
Angola Physical Therapy Pc Physical Therapist - Orthopedic Medicare: Medicare Enrolled Practice Location: 8505 Erie Rd., Angola, NY 14006 Phone: 716-549-1099 Fax: 716-549-2293 |
Dr. Mary Sharon Werth, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 8505 Erie Rd, Angola, NY 14006 Phone: 716-549-1099 Fax: 716-549-2293 |
Alisa Novack, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 8691 N Main St, Angola, NY 14006 Phone: 716-450-4510 |
Kristin Jordan Physical Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8685 Erie Rd, Angola, NY 14006 Phone: 716-549-4454 |
Ms. Jennifer Ann Steiger, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 636 Hickory Rd, Angola, NY 14006 Phone: 716-549-2516 |
Dr. Sean Kevin Mcgarrity, PT DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: Angola Physical Therapy, P.c., 8505 Erie Rd., Angola, NY 14006 Phone: 716-549-1099 Fax: 716-549-2293 |
News Archive
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
Night-time hemodialysis patients may have a greater capacity to repair their hearts and blood vessels compared to those on conventional dialysis three times a week, according to a study in the October issue of the American Journal of Physiology - Renal Physiology, published by the American Physiological Society.
Doing the human papillomavirus (HPV) test twice with a short interval between tests would reduce the number of women having unnecessary treatment, new research shows.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share.
› Verified 7 days ago